pyruvate kinase
Showing 1 - 25 of 2,135
Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia Trial in Worldwide
Recruiting
- Pyruvate Kinase Deficiency
- +3 more
-
Boston, Massachusetts
- +4 more
Aug 5, 2022
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia Trial in Barcelona, Madrid (Mitapivat, Mitapivat-matching )
Recruiting
- Pediatric Pyruvate Kinase Deficiency
- Pediatric Hemolytic Anemia
- Mitapivat
- Mitapivat-matching placebo
-
Barcelona, Spain
- +1 more
Aug 8, 2022
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia Trial in Spain, United States (Mitapivat, Mitapivat-matching )
Recruiting
- Pediatric Pyruvate Kinase Deficiency
- Pediatric Hemolytic Anemia
- Mitapivat
- Mitapivat-matching placebo
-
Phoenix, Arizona
- +3 more
Aug 8, 2022
Pyruvate Kinase Deficiency Trial in Stanford, Madrid (RP-L301)
Recruiting
- Pyruvate Kinase Deficiency
- RP-L301
-
Stanford, California
- +2 more
Sep 22, 2021
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Not yet recruiting
- Pyruvate Kinase Deficiency
- +10 more
- Blood Draw
-
Boston, MassachusettsMassachusetts General Hospital
May 21, 2021
Pyruvate Kinase Deficiency, Anemia, Hemolytic Trial in Canada, Japan (Mitapivat)
Not yet recruiting
- Pyruvate Kinase Deficiency
- Anemia, Hemolytic
-
Hamilton, Ontario, Canada
- +3 more
Mar 9, 2023
Pyruvate Kinase Deficiency, Anemia, Hemolytic Trial in Worldwide (AG-348)
Completed
- Pyruvate Kinase Deficiency
- Anemia, Hemolytic
-
Oakland, California
- +18 more
Dec 14, 2021
Healthy Subject, Intracranial Tumor, Glioblastoma Trial in Palo Alto (Fluorine F 18 DASA-23, Positron Emission Tomography)
Recruiting
- Healthy Subject
- +2 more
- Fluorine F 18 DASA-23
- Positron Emission Tomography
-
Palo Alto, CaliforniaStanford University, School of Medicine
Sep 2, 2021
Pyruvate Kinase Deficiency, Anemia, Hemolytic Trial in Worldwide (Placebo, AG-348)
Completed
- Pyruvate Kinase Deficiency
- Anemia, Hemolytic
- Placebo
- AG-348
-
Little Rock, Arkansas
- +45 more
May 20, 2022
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)
Unknown status
- Pyruvate Kinase Deficiency
-
Pembroke Pines, FloridaIntervent Clinical Research Center
Nov 23, 2020
Solid Tumors, Adult, PIK3CA Mutation-Related Tumors, PIK3CA Mutation Trial in San Francisco (Alpelisib, Carboplatin,
Not yet recruiting
- Solid Tumors, Adult
- +7 more
- Alpelisib
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jul 21, 2022
Pyruvate Kinase Deficiency, Congenital Non-Spherocytic Hemolytic Anemia Trial in Worldwide
Completed
- Pyruvate Kinase Deficiency
- Congenital Non-Spherocytic Hemolytic Anemia
-
Phoenix, Arizona
- +29 more
May 20, 2020
Image, Warburg Effect, Tumors Trial in Baltimore (Hyperpolarized 13C-Pyruvate)
Not yet recruiting
- Image
- +2 more
- Hyperpolarized 13C-Pyruvate
-
Baltimore, MarylandUniversity of Maryland Medical Center
Jan 30, 2023
Sickle Cell Disease, Hemolytic Anemia Trial run by the NHLBI (Mitapivat)
Active, not recruiting
- Sickle Cell Disease
- Hemolytic Anemia
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Sickle Cell Disease Trial in Worldwide (Etavopivat Tablets, Placebo Tablets)
Recruiting
- Sickle Cell Disease
- Etavopivat Tablets Low dose
- +3 more
-
Birmingham, Alabama
- +77 more
Oct 11, 2022
Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia,
Recruiting
- Autoimmune Hemolytic Anemia
- +5 more
- cytokine essays
- +6 more
-
Milano, ItalyFondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
Jul 3, 2023
Cardiac Transplant Metabolomics
Not yet recruiting
- Heart Transplant Rejection
- Extra blood samples (5-10 mL) drawn
- (no location specified)
Mar 17, 2023
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)
Recruiting
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
-
Ocala, Florida
- +3 more
Jan 30, 2023
Sport Performance Trial in Thessaloníki (Multi-ingredient dietary supplement (caffeine, creatine monohydrate, ß-alanine,
Active, not recruiting
- Sport Performance
- Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)
- Placebo dietary supplement (97% maltodextrin)
-
Thessaloníki, GreeceSports Nutrition Laboratory, International Hellenic University
Sep 30, 2023
Glioblastoma Multiforme Trial in Baltimore (Dichloroacetate (DCA), Genotype)
Recruiting
- Glioblastoma Multiforme
- Dichloroacetate (DCA)
- Genotype
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aug 26, 2022
Hyperpolarized MRSI in Ischemic Heart Disease: A Metabolic
Recruiting
- Ischemic Heart Disease
- 13C-enriched pyruvate
-
Aarhus, Region Midtjylland, DenmarkAarhus University Hospital
Sep 20, 2023
Idiopathic Pulmonary Fibrosis Trial in Hialeah Gardens (20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray)
Recruiting
- Idiopathic Pulmonary Fibrosis
- 20mM sodium pyruvate nasal spray
- Saline Placebo control nasal spray
-
Hialeah Gardens, FloridaFamily First Medical Research Center
Sep 16, 2023
Sickle Cell Disease Trial in Atlanta (Etavopivat)
Not yet recruiting
- Sickle Cell Disease
-
Atlanta, GeorgiaEmory University Children's Healthcare of Atlanta
Feb 10, 2023
Traumatic Brain Injury, Subarachnoid Hemorrhage Trial (Hyperpolarized 13C-Pyruvate)
Not yet recruiting
- Traumatic Brain Injury
- Subarachnoid Hemorrhage
- Hyperpolarized 13C-Pyruvate
- (no location specified)
Oct 21, 2023
Prostate Adenocarcinoma, Prostate Cancer Trial in San Francisco (Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance
Recruiting
- Prostate Adenocarcinoma
- Prostate Cancer
- Hyperpolarized Carbon C 13 Pyruvate
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Oct 3, 2022